Johnson & Johnson launches VARIPULSE pulsed field ablation technology in Peru. Discover what this means for atrial fibrillation treatment and electrophysiology innovation.
Johnson & Johnson has presented 12-month pilot data from the OMNY-AF study evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation at the 2026 AF Symposium. The early pilot cohort reported high acute procedural success, no procedure-related adverse events, and a 12-month freedom from atrial fibrillation rate approaching 90 percent. The […]